News | September 02, 2014

Study Presented at ESC Shows Renal Denervation Reduces Recurrent AF After Ablation

(left) Angiography of the left renal artery (center) Renal ablation with the ablation catheter (right) Three-dimensional reconstructions with sites of radiofrequency ablation represented in red.

September 2, 2014 — Renal denervation reduces recurrent atrial fibrillation (AF) when performed with pulmonary vein isolation ablation in patients with AF and hypertension, according to research presented at the European Society of Cardiology (ESC) Congress by Alexander Romanov, M.D., from Russia.

"The prevalence of AF ranges from 1.5 percent to 2 percent in developed countries," said Romanov. "This arrhythmia is associated with increased mortality, a five-fold risk of stroke and a three-fold incidence of congestive heart failure. The vast majority of patients with AF also have arterial hypertension. Up to 10 percent of patients with arterial hypertension are resistant to modern drug treatment and have so-called resistant hypertension, which is associated with an increased risk of cardiovascular events."

Renal sympathetic denervation (RD) is a new method that may be effective for controlling resistant hypertension by reducing the hyperactivity of the renal sympathetic nerve. In addition to its anti-hypertensive effects, RD may also exert anti-arrhythmic effects, with reports suggesting a potential role for both AF and ventricular tachyarrhythmias. On the other hand, hypertension is an established risk factor for AF, and many cases of apparently "lone" AF can be attributed to latent hypertension.

Pulmonary vein isolation (PVI) is a treatment for patients with AF. This catheter ablation technique uses radiofrequency (RF) energy to destroy tissue on the veins that are generating extra electrical signals and causing AF.

The aim of the present study was to assess the impact of adding RD as an adjunct to PVI in patients with AF, and moderate or severe resistant hypertension on AF recurrences and blood pressure changes.

The data for this analysis were obtained from two prospective randomized and double blind studies. The analysis included 80 patients with a history of symptomatic drug refractory paroxysmal and persistent AF and moderate/severe resistant hypertension who underwent PVI and RD compared to PVI only.

The researchers found that RD reduced the likelihood of AF when performed with PVI in hypertensive patients. At 12 months follow-up, 63 percent of the patients who had PVI and RD were AF-free compared to 41 percent of patients in the PVI-only group.

The benefit was most dramatic in patients with severe drug resistant hypertension and those with persistent AF, although non-significant trends were also seen in patients with moderate hypertension and those with paroxysmal AF.  "We could speculate that the limited number of patients enrolled did not allow this trend to reach statistical significance," Romanov said. "The use of RD in moderate hypertension as well as the effect on paroxysmal AF deserves further investigation."

RD delivered significant reductions in systolic and diastolic blood pressure. Romanov said, "These results are compatible with those reported by previous trials in severe and moderate resistant hypertension. Moreover, in our study we used high frequency stimulation for confirming the acute effect of RD. We believe this is a critical measure of success of this procedure."

"We found that the addition of RD to PVI may be beneficial in patients with severe resistant hypertension and/or persistent AF," he said. "These results confirm our earlier findings but in a larger and more diverse cohort of patients. Additional and larger trials are needed to validate our results, and to assess the effects of combined treatment on maintenance of sinus rhythm and blood pressure control beyond one year.

For more information: www.congress365.escardio.org

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init